2023-510174-13-00招募中3 期
A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500μg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 1,019
- 试验地点
- 132
- 主要终点
- Annual rate of moderate and severe exacerbations over 52 weeks.
研究概览
简要总结
To evaluate the efficacy of two doses of CHF6001 add-on to maintenance triple therapy (free or fixed combination of ICS, LABA, LAMA) to reduce the rate of moderate and severe exacerbations after 52 weeks of treatment in comparison with maintenance triple therapy (i.e. placebo arm).
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Males and females aged ≥ 40 years with written informed consent obtained prior to any study related procedure.
- •Subjects are willing and able to be trained to use correctly the electronic devices with COPD questionnaires, to understand and to perform required outcome measurements of the protocol (e.g.spirometry maneuvers etc.) and ability to understand the risks involved.
- •Females are eligible to enter the study if they are of a. non- childbearing potential, b. childbearing potential, they must have a negative pregnancy test at screening and must agree to use one or more of the acceptable contraceptive measures.
- •Subjects with an established diagnosis of COPD with chronic bronchitis.
- •Current smokers or ex-smokers who quit smoking at least 6 months prior to screening visit, with a smoking history of at least 10 pack years.
- •A post-bronchodilator FEV1 < 50% of the patient predicted normal value and a postbronchodilator FEV1/FVC ratio < 0.7 after 400μg (4 puffs x 100μg) of salbutamol pMDI or equivalent dose of albuterol pMDI in the US.
- •A documented history (e.g. medical record verification) of at least one moderate or severe COPD exacerbation in the previous year.
- •Symptomatic subject at screening defined as having a CAT score ≥
- •Subjects prescribed with maintenance triple therapy (free or fixed combination of ICS, LABA, LAMA) according to GOLD 2020 recommendations, for at least 12 months prior to screening and receiving regular maintenance triple therapy for at least 3 months prior to the screening visit. ICS must be in an approved dose for COPD.
- •Subjects are willing and able to be trained to use correctly the DPI inhalers (NEXThaler®).
排除标准
- •Subjects with a diagnosis of current asthma.
- •Subjects with active cancer or a history of cancer (other than the lung) with full recovery less than 1 year after completing cancer therapy or any untreated localized carcinoma.
- •Subjects with a history of allergy or hypersensitivity to anticholinergics, β2-agonists,corticosteroids, PDE-4 inhibitors or any of the excipients contained in any of the formulations used in the trial or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the investigator's opinion would contra-indicate study participation.
- •Subjects under Roflumilast treatment within 6 months before study entry.
- •Subjects with a diagnosis of depression, generalized anxiety disorder, suicidal ideation or behavior that might, according to the investigator judgement, place the patient at undue risk.
- •Subjects who have clinically significant cardiovascular condition.
- •An abnormal and clinically significant 12-lead ECG finding in relation to the subject's medical history that results in active medical problem which may impact the safety of the patient according to investigator's judgement.
- •Subjects with a significant neurological disease including transient ischemic attack (TIA), stroke, seizure disorder or behavioural disturbances that in investigator's opinion, would place the patient at risk by participating to the study.
- •Subjects with a moderate or severe COPD exacerbation 4 weeks prior to study entry and during run-in period.
- •Pregnant and lactating women.
- •Subjects requiring long term (at least 15 hours daily) oxygen therapy for chronic hypoxemia.
- •Subjects with known α-1 antitrypsin deficiency as the underlying cause of COPD.
- •Subjects with primary diagnosis of emphysema not related to COPD.
- •Subjects with clinically significant respiratory disorders other than COPD.
- •Subjects with lung volume reduction surgery.
- •Subjects having lung cancer or a history of lung cancer with full recovery less than 1 year after completing cancer therapy.
结局指标
主要结局
Annual rate of moderate and severe exacerbations over 52 weeks.
Annual rate of moderate and severe exacerbations over 52 weeks.
次要结局
- •Change from baseline in SGRQ Total score at week 52 •Time to first moderate/severe exacerbation •Annual rate of severe exacerbations •Time to first severe exacerbation
- •Change from baseline in morning pre-dose of FEV1 at week 52 •Change from baseline in SGRQ Domain scores at week 52
- •SGRQ response (i.e., change from baseline in SGRQ score ≤-4) at week 52 •Change from baseline to last inter-visit period (week 40-52) in the average E-RS total and sub-scale scores
- •E-RS response (i.e., change from baseline in E-RS total score ≤ -2) at week 52 •Change from baseline to last inter-visit period (week 40-52) in the percentage of days without intake of rescue medication and in the average daily use of rescue medication (number of puffs/day)
- •Time to study medication discontinuation due to any reason •Time to first moderate or severe exacerbation or study medication discontinuation due to class related adverse events, lack of efficacy or death, (composite endpoint) and time to its individual components
研究者
GLOBAL CLINICAL DEVELOPMENT
Scientific
Chiesi Farmaceutici S.p.A.
研究点 (132)
Loading locations...
相似试验
招募中
2 期
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapyAsthma2022-502208-64-00Chiesi Farmaceutici S.p.A.340
招募中
3 期
A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss.Androgenetic Alopecia2023-504421-39-00Cassiopea S.p.A.629
已完成
4 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.2023-503233-22-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
招募中
1 期
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationNCT07259590Genfleet Therapeutics (Shanghai) Inc.126
尚未招募
2 期
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT07266155Longbio Pharma30